Claims for Patent: 12,364,675

Summary for Patent: 12,364,675

Title:	Treatment or prevention of cardiovascular events via the administration of a colchicine derivative
Abstract:	A method for reducing a composite endpoint risk of myocardial infarction (MI), stroke, coronary revascularization, unstable angina requiring hospitalization, cardiac arrest, and cardiovascular death in a subject including administering, orally once per day to the subject, a composition comprising about 0.5 total mg of (i) colchicine, (ii) a pharmaceutically acceptable salt of (i), or any combination of (i) and (ii), wherein the patient has at least one history of diabetes, a past myocardial infarction, an unstable angina, a coronary bypass surgery, and a coronary angioplasty; wherein the patient is also administered a daily dose of statin therapy; and wherein the composite endpoint risk in the subject is reduced relative to a dosing regimen where the patient receives standard secondary prevention therapy of a statin.
Inventor(s):	Mark Nidorf
Assignee:	Murray and Poole Enterprises Ltd
Application Number:	US18/631,405
Patent Claims:	1. A method for treating and/or reducing the risk of a cardiovascular event in a subject in need thereof comprising: administering to the subject a first dose of a composition in tablet form or liquid form comprising no more than about 0.5 or 0.6 total mg of (i) colchicine, (ii) a salt of (i), or any combination of (i)-(ii), and following thereafter administering additional doses of the composition once per day, wherein the subject is clinically stable when administered the first dose. 2. The method of claim 1, wherein prior to administering the colchicine to the subject, the subject undergoes or has undergone percutaneous transluminal coronary angioplasty (PTCA). 3. The method of claim 1, wherein the subject has been clinically stable for at least six months prior to being administered the first dose of the composition. 4. The method of claim 1, wherein the subject has or has a history of stable coronary artery disease. 5. The method of claim 1, wherein the cardiovascular event is myocardial infarction. 6. The method of claim 1, wherein the cardiovascular event is non-cardio-embolic ischemic stroke. 7. The method of claim 1, wherein the cardiovascular event is acute coronary syndrome, out-of-hospital cardiac arrest or noncardioembolic ischemic stroke. 8. The method of claim 1, further comprising co-administering to the subject a therapeutically effective amount of a second agent for the treatment and/or reduction of risk of the cardiovascular event in the subject. 9. The method of claim 8, wherein the second agent is a colchicine-compatible statin. 10. The method of claim 9, wherein the colchicine-compatible statin is selected from the group consisting of: (i) atorvastatin, (ii) fluvastatin, (iii) lovastatin, (iv) pitavastatin, (v) rosuvastatin, (vi) simvastatin, (vii), pravastatin, a salt of any of (i)-(vii), or any combination thereof. 11. The method of claim 1, wherein the composition is administered on a daily basis to the subject for between 24 and 44 months. 12. A method for treating and/or reducing the risk of a cardiovascular event in a subject in need thereof comprising: (a) applying a percutaneous transluminal coronary angioplasty (PTCA) treatment to the subject; (b) administering to the subject a first dose of a composition in tablet or liquid form comprising no more than about 0.5 or 0.6 total mg of (i) colchicine, (ii) a salt of (i), or any combination of (i)-(ii), and (c) following thereafter administering additional doses of the composition once per day, wherein the subject is clinically stable when administered the first dose. 13. The method of claim 12, wherein the subject has been clinically stable for at least six months prior to being administered the first dose of the composition. 14. The method of claim 12, wherein the subject has or has a history of stable coronary artery disease. 15. The method of claim 12, wherein the cardiovascular event is myocardial infarction. 16. The method of claim 12, wherein the cardiovascular event is non-cardio-embolic ischemic stroke. 17. The method of claim 12, wherein the cardiovascular event is acute coronary syndrome, out-of-hospital cardiac arrest or noncardioembolic ischemic stroke. 18. The method of claim 12, further comprising co-administering to the subject a therapeutically effective amount of a second agent for the treatment and/or reduction of risk of the cardiovascular event in the subject. 19. The method of claim 18, wherein the second agent is a colchicine-compatible statin. 20. The method of claim 19, wherein the colchicine-compatible statin is selected from the group consisting of: (i) atorvastatin, (ii) fluvastatin, (iii) lovastatin, (iv) pitavastatin, (v) rosuvastatin, (vi) simvastatin, (vii), pravastatin, a salt of any of (i)-(vii), or any combination thereof. 21. The method of claim 12, wherein the composition is administered on a daily basis to the subject for between 24 and 44 months. 22. A method for treating and/or reducing the risk of a cardiovascular event in a subject in need thereof comprising: administering to the subject a first dose of a composition in tablet form or liquid form comprising no more than about 0.5 or 0.6 total mg of (i) colchicine, (ii) a salt of (i), or any combination of (i)-(ii), wherein the composition is administered only once per day and no more than once per day for between 24 and 44 months, and wherein the subject is clinically stable for at least six months prior to being administered the first dose. 23. The method of claim 22, wherein prior to administering the colchicine to the subject, the subject undergoes or has undergone percutaneous transluminal coronary angioplasty (PTCA). 24. The method of claim 22, wherein the subject has or has a history of stable coronary artery disease. 25. The method of claim 22, wherein the cardiovascular event is myocardial infarction. 26. The method of claim 22, wherein the cardiovascular event is non-cardio-embolic ischemic stroke. 27. The method of claim 22, wherein the cardiovascular event is acute coronary syndrome, out-of-hospital cardiac arrest or noncardioembolic ischemic stroke. 28. The method of claim 22, further comprising co-administering to the subject a therapeutically effective amount of a second agent for the treatment and/or reduction of risk of the cardiovascular event in the subject. 29. The method of claim 28, wherein the second agent is a colchicine-compatible statin. 30. The method of claim 29, wherein the colchicine-compatible statin is selected from the group consisting of: (i) atorvastatin, (ii) fluvastatin, (iii) lovastatin, (iv) pitavastatin, (v) rosuvastatin, (vi) simvastatin, (vii), pravastatin, a salt of any of (i)-(vii), or any combination thereof.